Association of adrenal metastases with outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.

被引：0
|
作者：
Billon, Emilien
Dalban, Cecile
Oudard, Stephane
Chevreau, Christine
Laguerre, Brigitte
Barthelemy, Philippe
Borchiellini, Delphine
Geoffrois, Lionnel
Negrier, Sylvie
Joly, Florence
Thiery-Vuillemin, Antoine
Gross-Goupil, Marine
Rolland, Frederic
Priou, Frank
Mahammedi, Hakim
Tantot, Florence
Escudier, Bernard
Chabaud, Sylvie
Albiges, Laurence
Gravis, Gwenaelle
机构：
[1] Inst Paoli Calmettes, Marseille, France
[2] Ctr Leon Berard, Lyon, France
[3] Hop Europeen Georges Pompidou, Paris, France
[4] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[5] Ctr Eugene Marquis, Rennes, France
[6] Inst Cancerol Strasbourg Europe, Strasbourg, France
[7] Univ Cote dAzur, Ctr Antoine Lacassagne, Nice, France
[8] Ctr Alexis Vautrin, Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[9] Univ Lyon 1, Ctr Leon Berard, Dept Med Oncol, Lyon, France
[10] Ctr Francois Baclesse, Dept Med Oncol, Caen, France
[11] Univ Hosp Jean Minjoz, Besancon, France
[12] CHU Bordeaux, Hop St Andre, Bordeaux, France
[13] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France
[14] CHD Vendee Hop Oudairies, La Roche Sur Yon, France
[15] Ctr Jean Perrin, Clermont Ferrand, France
[16] UNICANCER, GETUG Grp, Paris, France
[17] Gustave Roussy, Villejuif, France
[18] Univ Paris Saclay, Gustave Roussy Canc Campus, Villejuif, France
[19] Aix Mareseille Univ, Inst Paoli Calmettes, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.348
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
348
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
    Albiges, Laurence
    Negrier, Sylvie
    Dalban, Cecile
    Chevreau, Christine
    Gravis, Gwenaelle
    Oudard, Stephane
    Laguerre, Brigitte
    Barthelemy, Philippe
    Borchiellini, Delphine
    Gross-Goupil, Marine
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [22] Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
    Derosa, L.
    Silva, C. Alves Costa
    Dalban, C.
    Colomba, E.
    Negrier, S.
    Chevreau, C. M.
    Gravis, G.
    Oudard, S. M.
    Laguerre, B.
    Barthelemy, P.
    Borchiellini, D.
    Gross-Goupil, M.
    Geoffrois, L.
    Rolland, F.
    Thiery-Vuillemin, A.
    Joly, F.
    Ladoire, S.
    Tantot, F.
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S681 - S681
  • [23] Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
    Rassy, Elie
    Dalban, Cecile
    Colomba, Emeline
    Derosa, Lisa
    Silva, Carolina Alves Costa
    Negrier, Sylvie
    Chevreau, Christine
    Gravis, Gwenaelle
    Oudard, Stephane
    Laguerre, Brigitte
    Barthelemy, Philippe
    Goupil, Marine Gross
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 488 - 494
  • [24] Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): A validation study within the NIVOREN GETUG-AFU 26 translational study.
    Carril-Ajuria, Lucia
    Naigeon, Marie
    Dalban, Cecile
    Desnoyer, Aude
    Rioux-Leclercq, Nathalie
    Sautes-Fridman, Catherine
    Meylan, Maxime
    Vano, Yann-Alexandre
    Beusenlick, Benoit
    Chouaib, Salem
    De Oliveira, Caroline
    Tantot, Florence
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    Chaput, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
    Desnoyer, A.
    Larive, A.
    Drubay, D.
    Lanoy, E.
    Vano, Y.
    Rioux-Leclercq, N.
    Chouaib, S.
    Beuselinck, B.
    Tantot, F.
    Escudier, B.
    Chaput, N.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 394 - 394
  • [26] Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
    Carril-Ajuria, Lucia
    Naigeon, Marie
    Dalban, Cecile
    Desnoyer, Aude
    Rioux-Leclercq, Nathalie
    Sautes-Fridman, Catherine
    Meylan, Maxime
    Vano, Yann-Alexandre
    Beusenlick, Benoit
    Chouaib, Salem
    de Oliveira, Caroline
    Tantot, Florence
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    Chaput, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.
    Mourey, Loic
    Dalban, Cecile
    Negrier, Sylvie
    Chevreau, Christine
    Gravis, Gwenaelle
    Thibault, Constance
    Laguerre, Brigitte
    Barthelemy, Philippe
    Borchiellini, Delphine
    Gross-Goupil, Marine
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.
    Runcie, Karie
    Ornstein, Moshe Chaim
    Saraiya, Biren
    Krishnamurthi, Venkatesh
    Lee, Byron H.
    Anderson, Christopher B.
    DeCastro, Guarionex Joel
    McKiernan, James M.
    Dallos, Matthew
    Mayer, Tina M.
    Marron, Melanie
    Kulik, Alexandria
    Singer, Eric A.
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study
    Carril-Ajuria, Lucia
    Desnoyer, Aude
    Meylan, Maxime
    Dalban, Cecile
    Naigeon, Marie
    Cassard, Lydie
    Vano, Yann
    Rioux-Leclercq, Nathalie
    Chouaib, Salem
    Beuselinck, Benoit
    Chabaud, Sylvie
    Barros-Monteiro, Janice
    Bougouin, Antoine
    Lacroix, Guillaume
    Colina-Moreno, Irelka
    Tantot, Florence
    Boselli, Lisa
    De Oliveira, Caroline
    Fridman, Wolf Herve
    Escudier, Bernard
    Sautes-Fridman, Catherine
    Albiges, Laurence
    Chaput-Gras, Nathalie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
  • [30] Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
    Ficial, Miriam
    Jegede, Opeyemi
    Sant'Angelo, Miriam
    Moreno, Sonia
    Braun, David A.
    Wind-Rotolo, Megan
    Pignon, Jean-Christophe
    Catalano, Paul J.
    Sun, Maxine
    Van Allen, Eliezer Mendel
    Freeman, Gordon J.
    Sharpe, Arlene
    Hodi, F. Stephen
    Motzer, Robert J.
    Wu, Catherine J.
    Atkins, Michael B.
    McDermott, David F.
    Shukla, Sachet A.
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345